" "
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ventana Launches VENTANA Gram Staining Kit

Published: Monday, October 28, 2013
Last Updated: Sunday, October 27, 2013
Bookmark and Share
Fully automated Gram stain on the benchmark special stains platform.

Ventana Medical Systems, Inc. (Ventana) has announced the global launch of the VENTANA Gram Staining Kit. Automated for use on the VENTANA BenchMark Special Stains instrument, the Gram Staining Kit aids pathologists in the most basic classification of bacteria into Gram-positive and Gram-negative bacteria in fixed tissue samples.

Gram stain classification is clinically useful as it provides an initial indication of the nature of a patient's infection.

The Gram stain is part of a family of histochemical special stains that many laboratories around the world still run manually.

In automating the stain, Ventana gives its customers an efficient and automated method to perform this technically challenging assay, enabling them to achieve increased productivity, consistency, and testing quality.

"Tissue diagnostics play a critical role in enabling accurate diagnosis and treatment decisions for cancer patients. Ventana is dedicated to providing laboratories, pathologists and their patients with novel assays, and we are empowering our customers to achieve greater efficiencies by automating common, yet labor-intensive tests like the Gram stain," says Mara G. Aspinall, President, Ventana Medical Systems, Inc.

The Gram Staining kit is the newest addition to the Ventana product offerings on the highly successful, fully automated BenchMark Special Stains platform launched in mid-2012.

The kit offers two counterstain options and testing protocol flexibility to meet pathologists' individual preferences.

"The new Gram Staining Kit will provide our customers visual consistency and clarity rarely achieved with manual Gram staining protocols. Our commitment to quality and advancing diagnostic consistency through world-class automation shines with this new product," says Adrian Ralph, Vice President, Primary Staining, Ventana Medical Systems, Inc.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Ventana Enters into Agreement with Merck KGaA
Agreement to develop companion diagnostic test for cancer treatment.
Saturday, July 12, 2014
Appropriate and Targeted Therapy: A Significant Step Towards Personalized Medicine?
Ventana Medical Systems, Inc., has entered a strategic collaboration agreement with Bayer Pharma AG to develop a molecular companion diagnostic test.
Tuesday, January 17, 2012
Scientific News
What do Banana Peels and Human Skin Have in Common?
Human skin and banana peels have something in common: they produce the same enzyme when attacked. By studying fruit, researchers have come up with an accurate method for diagnosing the stages of this form of skin cancer.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
Head Injury Patients Develop Brain Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
New Way to Identify Brain Tumor Aggressiveness
Looking at a brain tumor’s epigenetic signature may help guide therapy.
OncoCyte, The Wistar Institute Enter Global Licensing Agreement
Exclusive rights to commercialize biomarker assay follows years of positive collaboration on lung cancer diagnostic test.
Easier Diagnosis for Fungal Infection of the Lungs
A new clinical imaging method developed in collaboration with a University of Exeter academic may enable doctors to tackle one of the main killers of patients with weakened immune systems sooner and more effectively.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!